Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAAR: ST-920 Gene Therapy in Fabry Disease
NCT04046224Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Jul 2019
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 7
01
Overview
A Phase 2 trial of inlezifigene civaparvovec in Fabry disease (FD), sponsored by Sangamo Therapeutics. Started Jul 2019; status: completed.
02
Drugs
inlezifigene civaparvovec
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT04046224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046224.